NEW YORK, NY / ACCESSWIRE / June 22, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
SCWorx Corp. (NASDAQ:WORX)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/scworx-corp-loss-submission-form?prid=7474&wire=1
Lead Plaintiff Deadline: June 29, 2020
Class Period: April 13, 2020 - April 17, 2020
Allegations against WORX include that: (1) SCWorx's supplier for COVID-19 tests had previously misrepresented its operations; (2) SCWorx's buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) as a result, the Company's purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Enphase Energy, Inc. (NASDAQ:ENPH)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=7474&wire=1
Lead Plaintiff Deadline: August 17, 2020
Class Period: February 26, 2019 - June 17, 2020
Allegations against ENPH include that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Endo International Plc (NASDAQ:ENDP)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/endo-international-plc-loss-submission-form?prid=7474&wire=1
Lead Plaintiff Deadline: August 18, 2020
Class Period: August 8, 2017 - June 10, 2020
Allegations against ENDP include that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong